2seventy bio Operating Income

The latest operating income for TSVT is $-60M as of March 2025. That compares with $-230M in the prior-year period — up 74.4% year over year. Investors often review this figure alongside 2seventy bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, TSVT's operating income moved from $-230M to $-60M — a 74.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 2seventy bio's operating scale or balance-sheet position.

A operating income figure of $-60M for TSVT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting TSVT's operating income ($-60M), review year-over-year change from $-230M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.